4/ Key takeaways
📌 For PsA: cycling vs. swapping — no clear winner
📌 For axSpA: cycling may be better

💡 First quasi-experimental study directly comparing cycle vs. swap strategies

🌍 For now, this reinforces: "Don’t assume MOA switch is always better."
- Individualized decisions still key

#RMDOpen

3/ Main outcome: Drug retention
✅ For PsA: No statistically significant difference in drug retention between groups (HR 1.17; p=0.29)
✅ For axSpA: Cycle strategy had significantly better retention (HR 1.46; 95% CI: 1.03–2.07)
📉 Swap had consistently lower curves in both.

2/ Study design
📍Real-world data, single-center (NL)
📅 Change in local protocol in Dec 2019 created two groups:
🔁 Cycle strategy: TNFi→TNFi (up to 2019)
🔄 Swap strategy: TNFi→IL-17i (2019-2023)
👥 Patients with PsA or axSpA analyzed over 36 months for drug retention.
#RealWorldEvidence #RMDOpen